Table 2.
Univariate and multivariate logistic regression analysis of the odds ratio for different irAEs, controlling for multiple conditions.
| Variable | Category | Univariate | Multivariate | Univariate | Multivariate | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crude OR | 95%CI | p value | Adjusted OR | 95%CI | p value | Crude OR | 95%CI | p value | Adjusted OR | 95%CI | p value | ||
| Pulmonary toxicity | Gastrointestinal reaction | ||||||||||||
| Age | 65≤age<75 | 1.329 | 1.217–1.451 | <0.001 | 1.270 | 1.163–1.388 | <0.001 | 1.157 | 0.815–1.644 | 0.414 | 1.151 | 0.811–1.635 | 0.431 |
| ≥75 | 1.414 | 1.274–1.570 | <0.001 | 1.381 | 1.243–1.534 | <0.001 | 1.527 | 1.035–2.253 | 0.033 | 1.537 | 1.041–2.268 | 0.031 | |
| Sex | Male | 1.609 | 1.473–1.756 | <0.001 | 1.537 | 1.407–1.680 | <0.001 | 1.247 | 0.892–1.742 | 0.196 | |||
| Treatment modality | Combinational | 1.334 | 1.236–1.441 | <0.001 | 1.300 | 1.203–1.405 | <0.001 | 1.503 | 1.110–2.035 | 0.008 | 1.509 | 1.114–2.044 | 0.008 |
| Comorbidity | Yes | 1.236 | 0.694–2.201 | 0.472 | 0.000 | 0.000 | 0.997 | ||||||
| Myasthenia gravis | Adrenal insufficiency | ||||||||||||
| Age | 65≤age<75 | 1.576 | 0.914–2.718 | 0.102 | 1.559 | 1.133–2.146 | 0.006 | 1.505 | 1.092–2.074 | 0.012 | |||
| ≥75 | 3.031 | 1.751–5.246 | <0.001 | 1.365 | 0.925–2.013 | 0.117 | 1.354 | 0.917–1.999 | 0.127 | ||||
| Sex | Male | 0.795 | 0.516–1.226 | 0.299 | 1.411 | 1.028–1.936 | 0.033 | 1.341 | 0.976–1.843 | 0.070 | |||
| Treatment modality | Combinational | 0.768 | 0.502–1.177 | 0.226 | 1.481 | 1.123–1.953 | 0.005 | 1.432 | 1.084–1.892 | 0.011 | |||
| Comorbidity | Yes | 2.935 | 0.403–21.388 | 0.288 | 0.000 | 0.000 | 0.997 | ||||||
| Colitis | Myocarditis | ||||||||||||
| Age | 65≤age<75 | 1.103 | 0.920–1.323 | 0.289 | 1.248 | 0.898–1.733 | 0.187 | ||||||
| ≥75 | 1.079 | 0.865–1.345 | 0.501 | 1.018 | 0.670–1.547 | 0.933 | |||||||
| Sex | Male | 1.011 | 0.851–1.202 | 0.897 | 0.886 | 0.651–1.205 | 0.441 | ||||||
| Treatment modality | Combinational | 1.451 | 1.234–1.705 | <0.001 | 1.433 | 1.219–1.684 | <0.001 | 1.216 | 0.908–1.629 | 0.189 | |||
| Comorbidity | Yes | 0.403 | 0.056–2.911 | 0.368 | 1.418 | 0.196–10.278 | 0.729 | ||||||
| Hepatitis | Myositis | ||||||||||||
| Age | 65≤age<75 | 0.610 | 0.412–0.904 | 0.014 | 0.614 | 0.416–0.907 | 0.014 | 1.230 | 0.857–1.767 | 0.262 | |||
| ≥75 | 0.499 | 0.292–0.852 | 0.011 | 0.504 | 0.295–0.861 | 0.012 | 1.488 | 0.988–2.242 | 0.057 | ||||
| Sex | Male | 0.921 | 0.633–1.338 | 0.665 | 1.450 | 1.012–2.076 | 0.043 | ||||||
| Treatment modality | Combinational | 2.964 | 1.995–4.403 | <0.001 | 2.924 | 1.966–4.349 | <0.001 | 1.072 | 0.786–1.462 | 0.663 | |||
| Comorbidity | Yes | 4.277 | 1.035–17.673 | 0.045 | 3.063 | 0.736–12.740 | 0.124 | 3.248 | 0.788–13.383 | 0.103 | |||
| Hypophysitis | Encephalitis | ||||||||||||
| Age | 65≤age<75 | 0.921 | 0.587–1.446 | 0.721 | 0.857 | 0.591–1.242 | 0.415 | ||||||
| ≥75 | 0.392 | 0.183–0.839 | 0.016 | 1.281 | 0.857–1.915 | 0.228 | |||||||
| Sex | Male | 1.128 | 0.706–1.803 | 0.615 | 0.644 | 0.467–0.889 | 0.007 | 0.646 | 0.468–0.892 | 0.008 | |||
| Treatment modality | Combinational | 1.516 | 0.985–2.334 | 0.059 | 1.394 | 1.012–1.920 | 0.042 | 1.363 | 0.989–1.878 | 0.058 | |||
| Comorbidity | Yes | 0.000 | 0.000 | 0.997 | 0.000 | 0.000 | 0.997 | ||||||
| Skin reaction | Diabetes | ||||||||||||
| Age | 65≤age<75 | 1.092 | 0.847–1.409 | 0.496 | 1.226 | 0.942–1.595 | 0.130 | ||||||
| ≥75 | 0.957 | 0.695–1.319 | 0.790 | 1.121 | 0.811–1.550 | 0.488 | |||||||
| Sex | Male | 0.708 | 0.560–0.894 | 0.004 | 0.721 | 0.571–0.911 | 0.006 | 1.219 | 0.941–1.579 | 0.135 | |||
| Treatment modality | Combinational | 1.245 | 0.990–1.566 | 0.061 | 1.041 | 0.824–1.315 | 0.736 | ||||||
| Comorbidity | Yes | 0.000 | 0.000 | 0.997 | 1.798 | 0.438–7.381 | 0.416 | ||||||
| Thyroid toxicity | Hematologic toxicity | ||||||||||||
| Age | 65≤age<75 | 0.848 | 0.723–0.994 | 0.042 | 0.802 | 0.650–0.991 | 0.041 | 1.130 | 0.795–1.607 | 0.496 | |||
| ≥75 | 0.920 | 0.760–1.114 | 0.395 | 0.711 | 0.542–0.934 | 0.014 | 1.513 | 1.024–2.236 | 0.037 | ||||
| Sex | Male | 0.877 | 0.756–1.017 | 0.083 | 0.818 | 0.670–0.998 | 0.047 | 1.228 | 0.878–1.719 | 0.231 | |||
| Treatment modality | Combinational | 0.996 | 0.864–1.148 | 0.955 | 1.503 | 1.110–2.035 | 0.008 | 1.511 | 1.115–2.047 | 0.008 | |||
| Comorbidity | Yes | 1.632 | 0.654–4.072 | 0.294 | 1.187 | 0.290–4.864 | 0.812 | ||||||
| Neurologic toxicity | |||||||||||||
| Age | 65≤age<75 | 0.795 | 0.329–1.919 | 0.609 | |||||||||
| ≥75 | 0.174 | 0.022–1.348 | 0.094 | ||||||||||
| Sex | Male | 1.194 | 0.463–3.080 | 0.713 | |||||||||
| Treatment modality | Combinational | 1.202 | 0.510–2.831 | 0.674 | |||||||||
| Comorbidity | Yes | 0.000 | 0.000 | 0.998 | |||||||||
irAEs, immune-related adverse events; Yes, with irAEs; No, without irAEs. Statistically significant values are in bold (p < 0.05).